pazopanib / Generic mfg. - LARVOL DELTA

Tolerability and Treatment Duration of Recommended vs Reduced Starting Doses of Vascular Endothelial Growth Factor (VEGF) Tyrosine Kinase Inhibitors (TKI) in Patients with Renal Cell Carcinoma (RCC) (HOPA 2026) - "Eligible patients include adults (≥18 years) with metastatic ccRCC who initiated therapy with cabozantinib, lenvatinib, or axitinib between January 1, 2017, and December 31, 2024...Exclusion criteria include patients participating in a clinical trial, receiving of sunitinib, pazopanib, or Cometriq formulations, and filling at outside pharmacies or through patient assistance programs... Results Pending"

Clinical • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Fragment-recombination design of a dual VEGFR2/TIE2 inhibitor with sarcoma-selective cytotoxicity (AACR 2026) - "Lead compounds were compared with pazopanib, regorafenib, and sorafenib. At 10 µM, SMC-101-017 showed moderate early suppression (66-72% viability across all lines at 24 h) but selectively eliminated KHOS/NP and 143B by 48 h (25% and 7%, respectively) while preserving RAW264.7 viability (>100%) SMC-101-017 demonstrated potent, time-dependent cytotoxicity against osteosarcoma while sparing myeloid cells across a 4-fold dose range, distinguishing it from approved multi-kinase TKIs. These findings nominate SMC-101-017 for target validation and in vivo evaluation, and support fragment-based design for developing kinase inhibitors with improved therapeutic windows."

Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Novel inhibitors of BCRP and P-gp found among drugs used in the treatment of cancer (AACR 2026) - "Of the investigated compounds, cabozantinib (IC50 of 0.65 µM), midostaurin (0.69 µM), and entrectinib (5.8 µM) showed the strongest inhibition of BCRP. Nilotinib (1.0 µM), osimertinib (2.0 µM), and abemaciclib (2.4 µM) showed the strongest inhibition of the P-gp. The highest I2/IC50 ratios for BCRP were observed for mitotane (6190), cabozantinib (1730), and abiraterone (831). For P-gp, the highest I2/IC50 ratios were observed for nilotinib (2880), pazopanib (1580), and mitotane (1480)...The highest I1/IC50 ratios for BCRP were observed for doxorubicin (8.2), etoposide (2.8), and fosaprepitant (0.84). For P-gp, the highest I1/IC50 ratios were observed for amscarine (1.6), vinorelbine (0.55), and fosaprepitant (0.50)...Mechanistic static model for BCRP inhibitors suggested that cabozantinib, midostaurin, and apalutamide could almost fully inhibit intestinal BCRP, increasing the exposure to concomitantly administered rosuvastatin by 94%, 89%,..."

Breast Cancer • Oncology • Solid Tumor

MVGAE: A Multi-View Graph Auto-Encoder Model for Drug Prediction of Non-Small Cell Lung Cancer Based on Synthetic Lethality. (PubMed, Curr Issues Mol Biol) - "Furthermore, several of the predicted candidate drugs (such as PAZOPANIB) have been previously reported to play a positive role in NSCLC treatment. This study highlights MVGAE as a novel computational framework for drug repurposing and demonstrates how its integration with complementary models can effectively prioritize potential therapeutic targets and candidate drugs, providing a robust computational basis for precision treatment strategies."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • RAD51

Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases: A Single-Center Cross-Sectional Study From a Tertiary Care Center in Bangladesh. (PubMed, Cureus) - "The results reflect outcomes among reported SAEs; however, they should not be interpreted as statistically significant.  Conclusion This study highlights serious adverse outcomes associated with tocilizumab and other commonly used medications in real-world clinical practice. Although casualty cannot be established due to the limited sample size and observational design, the findings emphasize the importance of vigilant pharmacovigilance and cautious interpretation of treatment outcomes."

Adverse events • Journal • Observational data • Serious adverse event • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

The potential of mitochondrial permeability transition-driven necrosis-related genes in prognostic evaluation of colorectal cancer patients. (PubMed, Front Oncol) - "Immunoassays revealed that high-risk patients had 9 elevated immune checkpoints, while low-risk patients were more susceptible to pazopanib and temsirolimus. Real-time PCR (RT-qPCR) confirmed low levels of CASP7, PRKCB, and ENDOG mRNA in CRC tissues, with no significant difference between LMNB2 and GZMB. These findings highlight 5 MPTDN-associated prognostic genes in CRC, providing insights for individualized treatment and prognosis."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CASP7 • GZMB • LMNB2 • PRKCB

Reduced initial Pazopanib dosing strategy for recurrent, advanced, or metastatic sarcoma: A single center experience. (PubMed, J Oncol Pharm Pract) - "Treatment interruptions occurred in 45% of patients, and dose reductions in 30% of patients.ConclusionsLower starting dose of pazopanib did appear to reduce the risk of various side effects compared to the PALETTE trial, suggesting a potential benefit of this dosing strategy given similar clinical efficacy. Further comparative studies examining lower initial dose vs full-dose initiation are needed to determine differences in patient tolerability and clinical outcomes."

Journal • Cardiovascular • Fatigue • Hypertension • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Primary cardiac angiosarcoma with isolated superior vena cava syndrome: a case report. (PubMed, J Med Case Rep) - "Patients with cardiac angiosarcoma may present with atypical or nonspecific symptoms, such as with our patient presenting with isolated superior vena cava syndrome, and an atypical presentation may further delay the diagnosis. Late presenting cardiac angiosarcoma contributes to a worse prognosis and higher likelihood of metastasis at the time of diagnosis. Treatment typically includes chemotherapy and radiation but surgical excision, alone or in combination with other therapies, can provide the best prognosis. Early detection of cardiac angiosarcoma is crucial for improving outcomes."

Journal • Angiosarcoma • Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology • Pain • Pulmonary Disease • Sarcoma • Solid Tumor

Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype (ESMO 2025) - P3 | "Conclusions The study did not reach its primary endpoint, with no significant difference in PFS between the two arms. The safety profile was better with N+I than with P. QoL will be presented at the congress."

Clinical • Late-breaking abstract • Metastases • P3 data • Angiosarcoma • Chordoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

PAZ-GT PK Study: A green tea-pazopanib pharmacokinetic interaction study in healthy participants (ANZCTR) - P1 | N=15 | Completed | Sponsor: The University of Sydney | Recruiting ➔ Completed

Trial completion • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Immuno-molecular features and therapeutic implications of brain metastases in clear cell renal cell carcinoma patients. (PubMed, Genes Immun) - "No partial responses (PR) were observed upon ipilimumab/nivolumab (0%), and pazopanib (0%). PRs were rare upon nivolumab (14%), sunitinib (25%), axitinib (28%) and axitinib/pembrolizumab (33%), but higher upon cabozantinib/nivolumab (50%) and cabozantinib in monotherapy (64%)...Based on this translational and clinical data, cabozantinib is the optimal systemic therapy for m-ccRCC patients with BrM. As the presence of BrM impacts the choice of first-line treatment, we advise to screen for BrM at baseline, even in asymptomatic patients."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • AXL • CD8

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=630 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=129 | Active, not recruiting | Sponsor: Incyte Corporation | Trial completion date: Feb 2023 ➔ Dec 2024

Trial completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=129 | Active, not recruiting | Sponsor: Incyte Corporation | Trial completion date: Feb 2022 ➔ Feb 2023

Trial completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=630 | Not yet recruiting | Sponsor: Incyte Corporation

Metastases • Clear Cell Renal Cell Carcinoma • Renal Cell Carcinoma

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=129 | Completed | Sponsor: Incyte Corporation | Active, not recruiting ➔ Completed

Trial completion • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Advanced Angiosarcoma of the Scalp: Long-term remission following 12 months of Pembrolizumab (DKK 2026) - "Local relapse in December 2014 was treated sequentially with liposomal doxorubicin (complete response), paclitaxel (partial response), trabectedin (stopped for toxicity), and pazopanib (September 2016; no benefit). Scalp angiosarcoma commonly affects older adults, limiting treatment options and causing symptomatic local progression. Chemotherapy offers only temporary benefit. This case suggests PD-1 blockade can induce durable, possibly curative remission after a finite 12-month course."

Clinical • IO biomarker • Metastases • Angiosarcoma • Infectious Disease • Non-melanoma Skin Cancer • Pneumonia • Respiratory Diseases • Sarcoma • Solid Tumor • PD-L1

Real-world efficacy of nivolumab plus cabozantinib in metastatic renal cell carcinoma (mRCC) using the IMDC. (ASCO-GU 2026) - "The most commonly used second line drugs were Axitinib (27.6%) and Lenvatinib plus Everolimus (17.2%). Others included Sunitinib (6.9%), Pazopanib (6.9%), Tivozanib (6.9%), Pembrolizumab plus Lenvatinib (5.2%) and Belzutifan (3.4%)... In this real-world analysis, Nivolumab plus Cabozantinib achieved TTNT and OS comparable to those reported in CheckMate 9ER, albeit with a somewhat lower ORR (41.6% vs 55.7%), likely influenced by the inclusion of non-clear cell histology. Importantly, 2nd line TKIs demonstrated activity following Cabozantinib exposure, supporting its use in this treatment sequence. Baseline characteristics."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=129 | Active, not recruiting | Sponsor: Incyte Corporation | N=630 ➔ 129 | Trial completion date: Jun 2023 ➔ Jun 2020 | Trial primary completion date: May 2023 ➔ Aug 2018

Enrollment change • Trial completion date • Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=129 | Active, not recruiting | Sponsor: Incyte Corporation | Trial completion date: Jun 2020 ➔ Feb 2022

Trial completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (clinicaltrials.gov) - P3 | N=129 | Active, not recruiting | Sponsor: Incyte Corporation | Trial completion date: Feb 2025 ➔ Jun 2025

Trial completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Pembrolizumab after adriamycin-based chemotherapy in patients with soft-tissue sarcoma: A real-world comparative analysis of second-line efficacy (Sarcoma-RC 2026) - "Five cohorts meeting inclusion criteria were identified across 150 healthcare organizations: pembrolizumab (Pe), trabectedin (T), eribulin (E), gemcitabine plus docetaxel (GD), and pazopanib (Pa). Legal entity responsible for the study The authors. Funding Has not received any funding."

Clinical • Real-world • Real-world evidence • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Efficacy of subsequent therapy in patients with metastatic renal cell carcinoma of intermediate and poor risk following first-line immuno-oncology combinations. (ASCO-GU 2026) - " This multicenter retrospective study included pts with mRCC of IMDC intermediate and poor risk who received subsequent therapy after disease progression following first-line treatment with either dual immunotherapy (ipilimumab and nivolumab) or IO-TKI since 2020...The following second-line regimens included: TKIs (pazopanib, axitinib or sunitinib) as monotherapy in 37 pts (37%), lenvatinib plus everolimus in 46 pts (46%), cabozantinib in 14 pts (14%) and everolimus as monotherapy in 4 pts (3%)... In real-world clinical practice, second-line therapy demonstrates comparable progression-free survival in patients with mRCC regardless of prior IO-IO or IO-TKI treatment. The combination of lenvatinib and everolimus showed the most promising outcomes among second-line regimens, supporting its role as a preferred option in this setting."

Clinical • Immuno-oncology • Metastases • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Second-line therapy after ipilimumab and nivolumab in advanced renal cell carcinoma: A multicenter real-world study (GUARDIANS). (ASCO-GU 2026) - "Median OS was 38 months (95 %CI 20.7-55.3) and median PFS 15 months (95 %CI 8.2-21.9) with cabozantinib in second-line setting compared to a median OS of 16 months (95 %CI 10.1-21.9, p = 0.003) and median PFS of 7 months (95 %CI 5.1-8.9, p = 0.013) in the heterogeneous comparison group including sunitinib (11.3 %), axitinib, pazopanib (both 4.3 %), lenvatinib plus everolimus (3.2 %), tivozanib (2.2 %) and different IO/TKI combinations or study medication (e.g. belzutifan)... Our real-world data support the use of cabozantinib after disease progression on ipilimumab and nivolumab as first-line therapy of aRCC with robust efficacy. Updated results on response rate, survival data and safety will be available for ASCO GU 2026."

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

WHEN CANCER THERAPY BREAKS THE HEART: PREDICTING HEART FAILURE HOSPITALIZATIONS ON VEGFR INHIBITORS (ACC 2026) - " We retrospectively reviewed 290 cancer patients treated with axitinib, cabozantinib, lenvatinib, and pazopanib between 2015-2023... HF hospitalization is a significant toxicity of VEGFRI therapy, where many cases occur in patients without prior HF. These patients frequently developed LVH and MI, suggesting substantial cardiac injury. Hyperlipidemia and longer QTc independently identified patients at higher risk, potentially reflecting subclinical cardiovascular disease."

Clinical • Congestive Heart Failure • Dyslipidemia • Heart Failure • Myocardial Infarction • Oncology